



## Case Reports

# Steroid Refractory Immune Checkpoint Induced Acute Interstitial Nephritis Salvaged by Mycophenolate Mofetil

Prashanth Moku<sup>1,2</sup>, Brianna Bakow<sup>1,2</sup>, Arun Muthiah<sup>3</sup>, Mark Birkenbach<sup>1,5</sup>, Matthew Austin<sup>4</sup>

<sup>1</sup> Alpert Medical School, Brown University,

<sup>2</sup> Division of Internal Medicine, Rhode Island Hospital,

<sup>3</sup> Department of Acute Medicine, Louis Stokes Cleveland VA Medical Center,

<sup>4</sup> Department of Internal Medicine, Yale University,

<sup>5</sup> Department of Pathology and Laboratory Medicine, Rhode Island Hospital

Journal of Brown Hospital Medicine

Vol. 2, Issue 2, 2023

## Article Information

Keywords: Immune checkpoint inhibitors, immune-related adverse events, bladder cancer, pneumonitis, acute interstitial nephritis, mycophenolate mofetil

<https://doi.org/10.56305/001c.74097>

Submitted: January 24, 2023  
EST

Accepted: March 31, 2023 EST

## Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized the field of medical oncology. This class of medications block molecules responsible for inhibiting the immune response to cancer, allowing for immune system activation, tumor recognition and destruction of cancer cells. A unique side-effect of these drugs involves the immune-mediated destruction of healthy tissue, known as immune-related adverse events (irAEs). One example is the autoimmune destruction of renal tissue associated with development of acute interstitial nephritis (AIN). Here, we present a case of a patient with metastatic bladder cancer treated with an ICI who developed AIN that was refractory to glucocorticoid therapy and salvaged by mycophenolate mofetil. The case illustrates the unique mechanism by which toxicity can occur, demonstrates the concept of delayed irAEs, and highlights the prolonged, durable responses patients with cancer can have to immunotherapy, even after treatment is discontinued.

## BACKGROUND


Immune checkpoint inhibitors (ICIs) have revolutionized the field of medical oncology and have been shown to increase survival in many different tumor types.<sup>1</sup> ICIs are monoclonal antibodies that block molecules responsible for inhibiting the immune response to cancer. This allows for T-cell activation, tumor recognition and immune-mediated destruction of cancer cells. The two primary groups include: inhibitors of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a key inhibitory molecule involved in antigen presentation; and inhibitors of programmed cell death (PD-1) or its ligand, programmed cell death protein ligand 1 (PD-L1).<sup>2</sup>

A unique side-effect profile of ICIs is an overactivation of the immune system resulting in autoimmune destruction of otherwise healthy tissue, known as immune-related adverse events (irAEs). While rare, one irAE is the autoimmune destruction of renal parenchyma and the development of acute interstitial nephritis (AIN).<sup>2</sup> Here, we present a patient with metastatic bladder cancer treated with pembrolizumab (an inhibitor of PD-1) who developed AIN, refractory to glucocorticoid therapy and salvaged by mycophenolate mofetil. In the context of clear metastatic disease and the development of multiple irAEs, patient had a complete response to his im-

muno-therapy and remains in complete radiographic response more than 12 months later.


## CASE PRESENTATION

Patient is a 68-year-old male with prior history of nicotine dependence, chronic kidney disease (previous baseline creatinine ~1.3 to 1.4 mg/dL), and muscle invasive bladder cancer. He was initially diagnosed with Stage IIIA (cT3, cN0, cM0) disease<sup>3</sup> in October 2019 and completed four cycles of neoadjuvant chemotherapy with gemcitabine and cisplatin followed by cystoprostatectomy.<sup>3</sup> At time of surgical resection, he had persistent T3 disease. One year later, he was found to have metastatic recurrence to the lungs, right hilar nodes, and perineum (**Figure 1a**). The National Comprehensive Cancer Network guidelines for first-line therapy of metastatic bladder cancer is determined by cisplatin eligibility.<sup>3</sup> In this patient with a prior poor response to neoadjuvant cisplatin-based chemotherapy, pembrolizumab monotherapy was chosen as front-line treatment for metastatic disease. After 10 cycles, he was incidentally found to have grade 1 pneumonitis on routine CT scan (**Figure 1b**). Pembrolizumab was held, and he was treated with a 1-month course of prednisone 1 mg/kg. Repeat CT chest after completion of steroids showed improvement of



**Figure 1.**

**Figure 1a:** CT chest scan demonstrating pulmonary metastatic disease, including right lung nodules (shown above). **Figure 1b:** CT chest showing multifocal ground-glass opacities and consolidative opacities concerning for drug-related pneumonitis. **Figure 1c:** CT chest showing complete resolution of lung nodule.



**Figure 2.** H&E (A) and PAS (B) stained sections showing intense interstitial and tubular intraepithelial inflammation consisting predominantly of mononuclear cells, consistent with immune checkpoint inhibitor-induced AIN

pneumonitis and a near complete radiographic response of his cancer ([Figure 1c](#)). He was not re-challenged with further pembrolizumab.

Two months after his last dose of pembrolizumab, the patient presented to the hospital with fever and dyspnea. His lab work-up was notable for serum creatinine elevated to 2.97 mg/dL from baseline 1.3 mg/dL. Chest and abdominal CT scan showed new multifocal patchy airspace disease concerning for recurrent drug-induced pneumonitis versus infection. He was found to be COVID-19 positive with an unrevealing bronchoscopy, and his respiratory symptoms improved with antibiotics alone. His renal function continued to worsen, and serum creatinine peaked at 7.51 mg/dL over a span of 10 days ([Figure 4](#)). Microscopic visualization of patient's urine sediment showed renal tubular epithelial (RTE) cells as well as RTE casts. The leading differential was acute kidney injury due to acute tubular necrosis (ATN) in setting of multifactorial pre-renal etiology (volume depletion versus NSAID-use versus infection). However, given progressive renal decline and concern for an autoimmune process, patient ultimately underwent a renal biopsy that revealed interstitial inflammation, tubular necrosis, and glomerulosclerosis, confirmatory for ICI-induced AIN ([Figure 2](#)).


Patient was initially treated with IV methylprednisolone 500mg alone for two days without improvement in renal function. Given concern for steroid refractory AIN and impending dialysis needs, second-line mycophenolate mofetil (MMF) was added at a dose of 1000mg twice daily. After initiation of MMF therapy, patient's renal function rapidly improved over 3-4 days ([Figure 3](#)). He was then discharged on prednisone 1mg/kg and mycophenolate mofetil 1000mg twice daily.

Patient received oral MMF 1000mg twice daily for a total of 10 days in addition to a prolonged taper of prednisone over a period of 4 months with close monitoring of his kidney function. He had a near complete recovery of his renal function. Most notably, the patient remains in complete remission, with most recent CT scan showing no evidence of recurrent disease despite being off pembrolizumab for approximately 15 months.

## DISCUSSION

Immune-related adverse events are common autoimmune side-effects seen with ICIs. In instances where anti-CTLA-4 inhibitors are used in combination with anti-PD-1 inhibitors, grade 3/4 irAEs can occur in up to 50-60% of patients.<sup>4</sup> When anti-PD-1/PD-L1 inhibitors are used as monotherapy, incidence of toxicity is lower, with grade 3/4 irAEs occurring in 20-30% of patients.<sup>4</sup> Given the expanding role ICI's play in medical oncology, the prevalence of these toxicities continues to increase. It is critical that providers understand the unique mechanism and adverse effect profile of ICI's to ensure prompt recognition and treatment.

Acute interstitial nephritis from ICIs is relatively rare and, as highlighted in the case above, can be difficult to diagnose. Like other etiologies of AIN, patients have subnephrotic range proteinuria and pyuria, but most ICI-induced AIN cases lack eosinophilia, fevers, and rashes.<sup>5</sup> <sup>6</sup> The temporal heterogeneity and variable time course from ICI-exposure to onset of acute kidney injury (AKI) is also unique with a recent review showing a time course



**Figure 3.** Serum creatinine levels since initiation of pembrolizumab.

Day 0 = initiation of check-point inhibitor. Arrow indicates initiation date for glucocorticoids during hospital admission.

from exposure toxicity ranging from 21 to 245 days.<sup>7</sup> These atypical characteristics of AIN due to ICI can complicate the diagnosis and lead to interruptions of immunosuppressive therapy. In the case presented above, there were several confounding factors that delayed a renal biopsy for definitive diagnosis.

The exact mechanism by which ICI therapy results in AIN is not entirely clear. The variable time course and delayed onset of AKI suggests a distinct mechanism from a traditional delayed hypersensitivity reaction seen in other types of drug-induced AIN. It is hypothesized that PD-L1 expression in the proximal tubules of the kidney is critical for immune tolerance from self-reactive T-cells.<sup>1, 8, 9</sup> Exposure to PD-1/PD-L1 inhibitors disrupt this immune homeostasis resulting in T-cell mediated destruction of proximal tubular cells.<sup>1, 8, 9</sup>

Glucocorticoids remain the standard of treatment for ICI-induced AIN based on published guidelines.<sup>10</sup> In a recent review, 9 of the 10 patients with ICI-induced AIN treated with glucocorticoids had complete or partial recovery of their renal function.<sup>5-7</sup> In a multi-center analysis of 138 patients with ICI-associated AKI, 86% of whom were treated with steroids, a complete response was seen in 40% of the patients, partial recovery in 45%, and no recovery in 15% of the patients.<sup>2</sup> It was also shown that a higher weight-based dose of prednisone correlated with a higher rate of complete response versus a partial response (median 0.77 mg/kg versus 0.66 mg/kg).<sup>2</sup> Unfortunately, for the patient described in this case, we did not see a robust response to high doses steroids alone, likely due to diagnostic challenges causing a delay in introduc-

tion of immunosuppressive therapy. He was started on second-line mycophenolate and ultimately achieved near complete recovery of his renal function.

MMF is a prodrug of mycophenolic acid that inhibits synthesis of guanosine nucleotides. Notably, MMF targets type II Inhibitor of Inosine Monophosphate Dehydrogenase (IMPDH) that are more preferentially expressed in activated forms of T and B lymphocytes.<sup>11</sup> MMF is used widely in treatment of autoimmune hepatitis (including in ICI-treated patients), and thereby clinicians have expanded the utility of MMF in treatment of other irAEs.<sup>11</sup> Review of recent literature also demonstrated that AIN patient refractory to steroid-therapy who were treated with MMF had at least partial recovery of renal function.<sup>7</sup> Literature also described utilization of MMF in cases where administration of high-dose steroids is contraindicated (i.e. newly diagnosed type I diabetics).<sup>11</sup> In this patient's treatment course, diagnostic complications delayed initiation of immunosuppressive agents, leading to concern that treatment with glucocorticoid therapy alone may not fully achieve suppression of immune-mediated toxicity. Hence, prompt treatment with an additional immunosuppressant, specifically MMF, was deemed necessary for further therapeutic management of the patient's worsening renal function.

In the case above, the patient had multiple irAEs, including both nephritis and pneumonitis. Despite the discontinuation of pembrolizumab in a patient with metastatic disease, he remains in complete remission almost 36 months after diagnosis. There have been several retrospective reviews showing an association between in-

creased survival and the development of irAEs.<sup>12</sup> Moreover, it has been shown that patients with multiple irAEs have a significant longer overall survival (OS) than patients with one irAE.<sup>13</sup> It is felt that the development of autoreactivity may be reflective of an effector T-cell response to the tumor, and in the process, T-cells become exposure and activated to antigens/epitopes that are shared by both the tumor and healthy tissue.<sup>1,9</sup>

It is important to acknowledge that the patient above had ICI-induced AIN despite being off pembrolizumab for over 2 months. There is a growing body of literature supporting the concept of delayed irAEs, immune toxicity that occurs months to years after discontinuation of ICIs.<sup>10</sup> This is an entity that is poorly understood, underdiagnosed, and unreported as many clinical trials stop reporting adverse events after 90 days. These delayed irAEs are likely related to the long half-life of these drugs (pembrolizumab has a half-life of 22 days) and a fundamental, long-term change to the homeostasis of a patient's immune system.

Overall, early recognition of ICI-AIN is warranted to ensure prompt treatment initiation. In cases of diagnostic uncertainty, a renal biopsy is an important tool to help guide the role of immunosuppressive therapy. Glucocorticoids show mostly favorable response rates, do not affect patient survival or time to treatment failure, and should be utilized promptly to treat ICI-induced AIN.<sup>14</sup> There is a clear association between irAEs and treatment efficacy, which leads to greater patient progression free and overall survival. Unfortunately, there is very little prospective data to guide how to best rechallenge these patients with ICIs moving forward, which involves a risk-benefit analysis with the patient and a multidisciplinary approach involving the Oncology and Nephrology team.

## Disclosures/Conflict of Interest

None of the authors have any disclosures nor conflict of interest

## Funding Information

None of the authors have received any funding for the above

## Author Contribution

All Authors have reviewed the final manuscript prior to submission. All the authors have contributed significantly to the manuscript, per the ICJME criteria of authorship.

- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- Drafting the work or revising it critically for important intellectual content; AND
- Final approval of the version to be published; AND
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

## CORRESPONDING AUTHOR

Matthew Austin, MD  
Yale University School of Medicine  
Smilow Cancer Hospital Care Center  
25 Wells St. 2<sup>nd</sup> floor Westerly, RI 02891  
Phone: 475-301-3718  
Email: [matthew.austin@yale.edu](mailto:matthew.austin@yale.edu)



This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CCBY-NC-4.0). View this license's legal deed at <https://creativecommons.org/licenses/by-nc/4.0> and legal code at <https://creativecommons.org/licenses/by-nc/4.0/legalcode> for more information.



## REFERENCES

1. Belliere J, Meyer N, Mazieres J, et al. Acute interstitial nephritis related to immune checkpoint inhibitors. *Br J Cancer*. 2016;115(12):1457-1461. doi:10.1038/bjc.2016.358
2. Manohar S, Ghamrawi R, Chengappa M, et al. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy. *Kidney360*. 2020;1(1):16-24. doi:10.34067/kid.0000152019
3. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines). Bladder Cancer. 2023. [http://www.nccn.org/professionals/physician\\_gls/pdf/bladder.pdf](http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf)
4. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N Engl J Med*. 2019;381(16):1535-1546. doi:10.1056/nejmoa1910836
5. Clarkson MR. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. *Nephrol Dial Transplant*. 2004;19(11):2778-2783. doi:10.1093/ndt/gfh485
6. González E, Gutiérrez E, Galeano C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. *Kidney Int*. 2008;73(8):940-946. doi:10.1038/sj.ki.5002776
7. Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. *Kidney Int*. 2016;90(3):638-647. doi:10.1016/j.kint.2016.04.008
8. Gros A, Parkhurst MR, Tran E, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. *Nat Med*. 2016;22(4):433-438. doi:10.1038/nm.4051
9. Spanou Z, Keller M, Britschgi M, et al. Involvement of Drug-Specific T Cells in Acute Drug-Induced Interstitial Nephritis. *Journal of the American Society of Nephrology*. 2006;17(10):2919-2927. doi:10.1681/asn.2006050418
10. Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. *J Immunother Cancer*. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435
11. Jessel S, Austin M, Kluger HM. Mycophenolate as Primary Treatment for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report. *Clin Oncol Case Rep*. 2021;4(1).
12. Hussaini S, Chehade R, Boldt RG, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis. *Cancer Treatment Reviews*. 2021;92:102134. doi:10.1016/j.ctrv.2020.102134
13. Shimozaki K, Sukawa Y, Beppu N, et al. Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors. *Cancer Manag Res*. 2020;12:4585-4593. doi:10.2147/cmar.s247554
14. Horvat TZ, Adel NG, Dang TO, et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. *Journal of Clinical Oncology*. 2015;33(28):3193-3198. doi:10.1200/jco.2015.60.8448